Pfizer is buying this Botox-maker in the world’s largest pharma deal ever!
Advertisement
In what is said to be a colossal deal in pharmaceutical sector, US drug giant Pfizer is all set to buy Botox maker Allergan for whooping $150 million.
If everything goes as planned, the deal will give the $45-billion Pfizer the tax benefits of an Irish domicile.
Pfizer has been desperately looking to buy Allergan after its failed attempt to buy Anglo-Swedish drug maker AstraZeneca for $118 billion.
Allergan has morphed from being an ophthalmic-focused drug firm to a serious multiproduct branded industry heavyweight through a series of deals over the past three years.
As per reports, this historic deal will involve Pfizer paying with 11.3 of its shares for each Allergan share.
Pfizer will bring together its drugs such as Lipitor, Viagra and nerve pain treatment Lyrica with Allergan's Namenda memory loss treatment, Restasis dry eye medication and other leading eye-care brands.
A Reuters report quoted many industry analysts and investors, who believed that Pfizer could be bulking up with Allergan's fast-growing brands as a prelude to splitting by 2017 into two companies - one selling high-margin branded drugs and one selling inexpensive generics that have dragged down Pfizer results over the past few years.
Allergan was founded in 1948 By Gavin Herbert and the company first marketed its first nasal drop- Allergan.
(Image: Thinkstock)
Advertisement
If everything goes as planned, the deal will give the $45-billion Pfizer the tax benefits of an Irish domicile.
Pfizer has been desperately looking to buy Allergan after its failed attempt to buy Anglo-Swedish drug maker AstraZeneca for $118 billion.
Allergan has morphed from being an ophthalmic-focused drug firm to a serious multiproduct branded industry heavyweight through a series of deals over the past three years.
As per reports, this historic deal will involve Pfizer paying with 11.3 of its shares for each Allergan share.
Advertisement
A Reuters report quoted many industry analysts and investors, who believed that Pfizer could be bulking up with Allergan's fast-growing brands as a prelude to splitting by 2017 into two companies - one selling high-margin branded drugs and one selling inexpensive generics that have dragged down Pfizer results over the past few years.
Allergan was founded in 1948 By Gavin Herbert and the company first marketed its first nasal drop- Allergan.
(Image: Thinkstock)
Advertisement
- I got a $40K raise using this 30-second strategy. It made me realize loud work, not hard work, always wins.
- A millennial manager went viral after her Gen Z assistant picked up a work call while at the hair salon: 'Go off queen'
- Qatar Airways' new CEO explains why it's sticking with the Airbus A380 as other airlines retire the costly superjumbo
- Kia India looks to expand sales, service network to 700 touchpoints by year-end
- Shapoorji Pallonji’s Afcons Infra files DRHP for ₹7,000 crore IPO
- Water crisis affects businesses across Bengaluru; Is there room for cautious optimism?
- BenQ Zowie EC2-CW review – Premium wireless mouse for gamers
- Banks' GNPAs set to improve further to 2.1 pc by FY25: Care Ratings